300
Participants
Start Date
July 31, 2006
Primary Completion Date
October 31, 2007
Study Completion Date
January 31, 2008
Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)
New York
Mount Vernon
Brooklyn
Albany
Rochester
Philadelphia
Washington D.C.
Baltimore
Annandale
Hampton
Winston-Salem
Greenville
Charlotte
Decatur
Atlanta
Pensacola
Orlando
Vero Beach
Hollywood
Miami
Fort Lauderdale
Tampa
Safety Harbor
Port Saint Lucie
Hobson City
Akron
Indianapolis
Berkley
Grosse Pointe Woods
Minneapolis
Aurora
Chicago
St Louis
Dallas
Houston
Harlingen
Denver
Phoenix
Los Angeles
Beverly Hills
Long Beach
Tarzana
San Diego
San Francisco
Oakland
Spokane
Norwalk
Boston
Springfield
Hillsborough
Newark
Newark
Somers Point
Providence
Ponce
San Juan
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Gilead Sciences
INDUSTRY